Overview

Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Metastatic Melanoma of the Eye That Cannot Be Removed By Surgery

Status:
Completed

Trial end date:
2013-04-01

Target enrollment:

Participant gender:

Summary

RATIONALE: Drugs used in chemotherapy, such as paclitaxel albumin-stabilized nanoparticle formulation, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. PURPOSE: This phase II trial is studying how well paclitaxel albumin-stabilized nanoparticle formulation works in treating patients with metastatic melanoma of the eye that cannot be removed by surgery.

Phase:

Phase 2

Details

Lead Sponsor:

Ohio State University Comprehensive Cancer Center

Collaborators:

Celgene Corporation
National Comprehensive Cancer Network

Treatments:

Albumin-Bound Paclitaxel
Paclitaxel